Researcher.Life Logo

Clinical Pharmacology and Therapeutics : Impact Factor & More

eISSN: 1532-6535pISSN: 0009-9236

Key Metrics

CiteScore
10.7
Impact Factor
5 - 10
Scite Index
0.89 5-Year SI
SNIP
1.83
Recommended pre-submission checks
Powered by Paperpal by Editage

Clinical Pharmacology and Therapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
Overview
Publisher WILEY
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1960
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Clinical Pharmacology and Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Clinical Pharmacology and Therapeutics

Title not available
  • 1 Jun 2026
  • Clinical Pharmacology & Therapeutics
Balancing Reassurance and Vigilance: Real-World Evidence in Post-Marketing Drug Safety.
  • 1 Jun 2026
  • Clinical pharmacology and therapeutics
Correction to "Real-World Outcomes of Pembrolizumab Monotherapy in Metastatic Non-Small Cell Lung Cancer by Age and Sex: A National Population-Based Study in Australia".
  • 1 Jun 2026
  • Clinical pharmacology and therapeutics
Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma.
  • 15 May 2026
  • Clinical pharmacology and therapeutics
Systems Pharmacology Approach to Paroxysmal Nocturnal Hemoglobinuria: Quantitative Framework for Biomarker Dynamics across Multi-Mechanistic Therapies.
  • 15 May 2026
  • Clinical pharmacology and therapeutics
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.
  • 15 May 2026
  • Clinical pharmacology and therapeutics
Title not available
  • 1 Jun 2026
  • Clinical Pharmacology & Therapeutics
Balancing Reassurance and Vigilance: Real-World Evidence in Post-Marketing Drug Safety.
  • 1 Jun 2026
  • Clinical pharmacology and therapeutics
Correction to "Real-World Outcomes of Pembrolizumab Monotherapy in Metastatic Non-Small Cell Lung Cancer by Age and Sex: A National Population-Based Study in Australia".
  • 1 Jun 2026
  • Clinical pharmacology and therapeutics
Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma.
  • 15 May 2026
  • Clinical pharmacology and therapeutics
Systems Pharmacology Approach to Paroxysmal Nocturnal Hemoglobinuria: Quantitative Framework for Biomarker Dynamics across Multi-Mechanistic Therapies.
  • 15 May 2026
  • Clinical pharmacology and therapeutics
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.
  • 15 May 2026
  • Clinical pharmacology and therapeutics

FAQs on Clinical Pharmacology and Therapeutics